Prescient Therapeutics Ltd
Prescient Therapeutics Limited is a clinical-stage oncology company.
The business
Prescient Therapeutics Limited is a clinical-stage oncology company. It is engaged in developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, CellPryme-M, and OmniCAR. PTX-100 is a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. PTX-100 is in a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma with Fast Track Designation. CellPryme-M is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. OmniCAR is a universal CAR platform that is controllable, with plug and play capabilities to enable a wider range of cancers to be targeted. OmniCAR enables controllable T-cell activity and multiantigen targeting with a single cell product.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Prescient Therapeutics’ First-in-Class Cancer Drug Approaching a Pivotal Moment
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b potential big-pharma partner as first-in-class GGT-1/RAS hit.
Prescient Therapeutics Moves Advanced PTX-100 Cutaneous T-Cell Lymphoma Therapy Closer to Commercialisation
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant market need, potentially converting years of work into billions of dollars. The company’s lead candidate PTX-100 is now in its all-important Phase 2 clinical trials. It is at this stage where data read-outs can provide […]
Prescient Therapeutics Confirms First US Site for PTX-100 Phase 2a Refractory Cutaneous T-Cell Lymphoma Trial
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL). The Massey Comprehensive Cancer Centre at Virginia Commonwealth University – ranked as one of the top cancer research centres in the […]
Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma (CTCL). Now in its Phase 2a trial, the advanced drug has delivered a 64% tumour halt or shrinkage in patients with […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.